10/602,692


```
=> fil reg
FILE 'REGISTRY' ENTERED AT 14:41:34 ON 30 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   29 AUG 2004  HIGHEST RN 735258-95-4
DICTIONARY FILE UPDATES:  29 AUG 2004  HIGHEST RN 735258-95-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d sta que l23
L20             STR
```




```
VAR G1=O/S/SO2/CH2
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT   IS PCY  AT   6
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS M3 N  AT   6

GRAPH ATTRIBUTES:
RSPEC   1
NUMBER OF NODES IS   8

STEREO ATTRIBUTES: NONE
L21       12715 SEA FILE=REGISTRY ABB=ON  PLU=ON  (N2C3-NCNC3 OR NCNC2-NC5 OR
                N3C2-NC5 OR N2CNC-NC5)/ES AND (OC4 OR SC4 OR C5)/ES
L23        2684 SEA FILE=REGISTRY SUB=L21 SSS FUL L20

100.0% PROCESSED   2966 ITERATIONS                          2684 ANSWERS
SEARCH TIME: 00.00.01


=> d his

     (FILE 'HOME' ENTERED AT 14:02:39 ON 30 AUG 2004)
               SET COST OFF

     FILE 'HCAPLUS' ENTERED AT 14:02:47 ON 30 AUG 2004
L1             1 S (US20040101535 OR US20030050229)/PN OR US2000-206585#/AP,PRN
               E SOMMADOSSI J/AU
```

cc/602, 692

~~OWENS 9 10 / 602276~~


```
L2          210 S E4,E5
                E LACOLLA P/AU
L3            5 S E4,E5
                E LA COLLA P/AU
L4          194 S E3-E7
                E COLLA /AU
                E NOVIRIO/PA,CS
L5           14 S E3-E17
                SEL RN L1

     FILE 'REGISTRY' ENTERED AT 14:04:34 ON 30 AUG 2004
L6           18 S E1-E18

     FILE 'HCAPLUS' ENTERED AT 14:06:43 ON 30 AUG 2004
L7          402 S L2-L5 NOT L1

     FILE 'REGISTRY' ENTERED AT 14:07:30 ON 30 AUG 2004

     FILE 'HCAPLUS' ENTERED AT 14:07:30 ON 30 AUG 2004
                SET SMARTSELECT ON
L8           SEL L7 1- RN :    5164 TERMS
                SET SMARTSELECT OFF

     FILE 'REGISTRY' ENTERED AT 14:07:45 ON 30 AUG 2004
L9          5164 S L8
L10         1007 S L9 AND OC4/ES
L11          646 S C2N3-C5N/EA AND OC4/ES
L12         3462 S C3N2-C5N/EA AND OC4/ES
L13         2889 S NCNC2-NC5/ES AND OC4/ES
L14          573 S L12 NOT L13
L15          497 S N2CNC-NC5/ES AND L11
L16          149 S N3C2-NC5/ES AND L11
L17          646 S L15,L16
L18         3655 S N2C3-NCNC3/ES AND OC4/ES
L19           76 S L9 AND L13,L17,L18
L20              STR
L21        12715 S (N2C3-NCNC3 OR NCNC2-NC5 OR N3C2-NC5 OR N2CNC-NC5)/ES AND (OC
L22           50 S L20 SAM SUB=L21
L23         2684 S L20 FUL SUB=L21
                SAV TEMP L23 OWENS602/A
L24           55 S L9 AND L23
L25           21 S L19 NOT L24
L26         2629 S L23 NOT L24

     FILE 'HCAPLUS' ENTERED AT 14:24:08 ON 30 AUG 2004
L27          287 S L24
L28         1420 S L26
L29         1434 S L27,L28 AND (PD<=20000523 OR PRD<=20000523 OR AD<=20000523)
                E HEPATITIS C/CT
L30         6755 S E5-E15
                E E5+ALL
L31         8412 S E8,E9,E6+NT
                E HEPATITIS C/CT
                E E3+ALL
L32         4192 S E2
L33        11890 S HEPATITIS C
L34            1 S L29 AND L30-L33
                E HEPATITIS/CT
L35        16169 S E3-E28
L36         1425 S E34+OLD,NT,PFT,RT
L37         9616 S E52+OLD,NT,PFT,RT
L38          754 S E76+OLD,NT,PFT,RT
L39          485 S E78+OLD,NT,PFT,RT
```

```
L40          15 S E79+OLD,NT,PFT,RT
L41         561 S E81+OLD,NT,PFT,RT
L42         512 S E85+OLD,NT,PFT,RT
L43        7978 S E90+OLD,NT,PFT,RT
               E E3+ALL
               E HEPATITIS VIRUS/CT
               E E3+ALL
L44        7978 S E4,E3
L45       43705 S HEPATITIS
L46           6 S L29 AND L35-L45
L47           3 S L1-L5 AND L27,L28
L48           9 S L34,L46,L47
L49           6 S L29 AND ?HEPATITIS?
L50           9 S L48,L49

     FILE 'REGISTRY' ENTERED AT 14:30:02 ON 30 AUG 2004
L51           6 S (RIBAVIRIN OR PROTEASE OR POLYMERASE OR HELICASE)/CN

     FILE 'HCAPLUS' ENTERED AT 14:30:39 ON 30 AUG 2004
L52          37 S L51 AND L29
L53          64 S (RIBAVIRIN OR PROTEASE OR PROTEINASE OR POLYMERASE OR HELICAS
L54           6 S INTERFERON AND L29

     FILE 'REGISTRY' ENTERED AT 14:31:29 ON 30 AUG 2004
L55           1 S THIAZOLIDINE/CN

     FILE 'HCAPLUS' ENTERED AT 14:31:32 ON 30 AUG 2004
L56           0 S L55 AND L29
L57           0 S THIAZOLIDIN? AND L29
L58          80 S L52-L54
L59          16 S L58 AND (MIX? OR COMBIN? OR SYNERG? OR COMPOSITION OR COTHERA
               SEL DN AN 13 L59
L60           1 S L59 AND E1-E3
L61          64 S L58 NOT L59
               SEL DN AN 14 18 25
L62           3 S L61 AND E4-E12
L63           1 S L62 AND HEPATITIS
L64          10 S L50,L60,L63
L65          10 S L64 AND L1-L5,L27-L50,L52-L54,L56-L64
               SEL  HIT RN

     FILE 'REGISTRY' ENTERED AT 14:40:10 ON 30 AUG 2004
L66          77 S E13-E89
L67           1 S L66 AND L51
L68          76 S L66 AND L23

     FILE 'REGISTRY' ENTERED AT 14:41:34 ON 30 AUG 2004

=> d ide can l67

L67  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   36791-04-5  REGISTRY
CN   1H-1,2,4-Triazole-3-carboxamide, 1-β-D-ribofuranosyl- (9CI)  (CA
     INDEX NAME)
OTHER NAMES:
CN   1-β-D-Ribofuranosyl-1,2,4-triazol-3-carboxyamide
CN   1-β-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
CN   ICN 1229
CN   NSC 163039
CN   Ravanex
CN   Rebetol
CN   Ribamide
CN   Ribamidil
```

CN Ribavarin
CN **Ribavirin**
CN Tribavirin
CN Vilona
CN Viramid
CN Virazole
FS STEREOSEARCH
DR 66510-90-5, 437710-49-1
MF C8 H12 N4 O5
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: WHO
DT.CA CAplus document type: Book; Conference; Dissertation; Journal; Patent; Report
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1977 REFERENCES IN FILE CA (1907 TO DATE)
71 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1985 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:162353

REFERENCE 2: 141:155723

REFERENCE 3: 141:140707

REFERENCE 4: 141:138913

REFERENCE 5: 141:133747

REFERENCE 6: 141:133621

REFERENCE 7: 141:128820

REFERENCE 8: 141:128600

REFERENCE 9: 141:122155

REFERENCE 10: 141:122153

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 14:41:56 ON 30 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 30 Aug 2004 VOL 141 ISS 10
FILE LAST UPDATED: 29 Aug 2004 (20040829/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l65 all hitstr tot

L65 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:41758 HCAPLUS
DN 132:194596
ED Entered STN: 18 Jan 2000
TI Synthesis and biological activity of 2'-fluoro-D-arabinofuranosylpyrazolo[3,4-d]pyrimidine nucleosides
AU Shortnacy-Fowler, Anita T.; Tiwari, Kamal N.; Montgomery, John A.; Buckheit, Robert W., Jr.; Secrist, John A., III; Seela, Frank
CS Southern Research Institute, Birmingham, AL, 35255-5305, USA
SO Helvetica Chimica Acta (1999), 82(12), 2240-2245
CODEN: HCACAV; ISSN: 0018-019X
PB Verlag Helvetica Chimica Acta
DT Journal
LA English
CC 33-9 (Carbohydrates)
Section cross-reference(s): 1
AB Coupling of 2-fluoro-3,5-di-O-benzoyl-α-D-arabinofuranosyl bromide with 4-methoxypyrazolo[3,4-d]pyrimidine gave an α-D/β-D mixture of N1-and N2-coupled products. All the anomers were separated and deblocked to yield the corresponding nucleosides. The β-D-anomer was converted to the 4-amino derivative, which was deaminated by adenosine deaminase to give the 4-oxo compound 1-(2-Deoxy-2-fluoro-β-D-arabinofuranosyl)-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine showed significantly activity against human cytomegalovirus and **hepatitis** B virus; its 4-amino analog showed activity against human herpes virus 8. All the compds. were non-cytotoxic in several human tumor-cell lines in culture.
ST pyrazolo pyrimidine nucleoside prepn virucide; fluoro arabinofuranosyl pyrazolopyrimidine nucleoside prepn antiviral antitumor

IT Antitumor agents
Antiviral agents
Cytotoxicity
(synthesis and biol. activity of fluoro-D-arabinofuranosyl pyrazolopyrimidine nucleosides)
IT Nucleosides, preparation
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and biol. activity of fluoro-D-arabinofuranosyl pyrazolopyrimidine nucleosides)
IT **259738-10-8P 259738-11-9P 259738-12-0P**
259738-13-1P 259738-14-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and biol. activity of fluoro-D-arabinofuranosyl pyrazolopyrimidine nucleosides)
IT 5399-93-9 97614-44-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis and biol. activity of fluoro-D-arabinofuranosyl pyrazolopyrimidine nucleosides)
IT **259738-06-2P 259738-07-3P 259738-08-4P**
259738-09-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and biol. activity of fluoro-D-arabinofuranosyl pyrazolopyrimidine nucleosides)
RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Brockman, R; Biochem Pharmacol 1977, V26, P2193 HCAPLUS
(2) Carson, D; Proc Natl Acad Sci U S A 1980, V77, P6065
(3) Jungmann, O; Tetrahedron Lett 1996, V37, P8355 HCAPLUS
(4) Kazimierczuk, Z; J Am Chem Soc 1984, V106, P6379 HCAPLUS
(5) Korba, B; Antiviral Res 1992, V19, P55 HCAPLUS
(6) Montgomery, J; Antimetabolites in ` Cancer Chemotherapeutic Agents,' 1995, P47
(7) Montgomery, J; J Med Chem 1992, V35, P397 HCAPLUS
(8) Parker, W; Mol Pharmacol 1999, V55, P515 HCAPLUS
(9) Robins, R; J Am Chem Soc 1956, V78, P784 HCAPLUS
(10) Secrist, J; J Med Chem 1998, V41, P3865 HCAPLUS
(11) Seela, F; Helv Chim Acta 1985, V68, P563 HCAPLUS
(12) Seela, F; Helv Chim Acta 1993, V76, P1450 HCAPLUS
(13) Seela, F; J Org Chem 1983, V48, P3119
(14) Seela, F; Nucleosides Nucleotides 1991, V10, P713 HCAPLUS
(15) Shaw, R; Cancer 1960, V13, P482 HCAPLUS
(16) Shoemaker, R; submitted
(17) Skipper, H; Cancer Res 1957, V17, P579 HCAPLUS
(18) Tann, C; J Org Chem 1985, V50, P3644 HCAPLUS
(19) Tatarowicz, W; J Virol Methods 1991, V35, P207 HCAPLUS
(20) Wright, S; Blood Rev 1994, V8, P125 MEDLINE
IT **259738-10-8P 259738-11-9P 259738-12-0P**
259738-13-1P 259738-14-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and biol. activity of fluoro-D-arabinofuranosyl pyrazolopyrimidine nucleosides)
RN 259738-10-8 HCAPLUS
CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 259738-11-9 HCAPLUS
CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-(2-deoxy-2-fluoro-α-D-arabinofuranosyl)-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 259738-12-0 HCAPLUS
CN 2H-Pyrazolo[3,4-d]pyrimidine, 2-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 259738-13-1 HCAPLUS
CN 2H-Pyrazolo[3,4-d]pyrimidine, 2-(2-deoxy-2-fluoro-α-D-arabinofuranosyl)-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 259738-14-2 HCAPLUS
CN 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **259738-06-2P 259738-07-3P 259738-08-4P**
259738-09-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and biol. activity of fluoro-D-arabinofuranosyl pyrazolopyrimidine nucleosides)

RN 259738-06-2 HCAPLUS
CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-(3,5-di-O-benzoyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 259738-07-3 HCAPLUS
CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-(3,5-di-O-benzoyl-2-deoxy-2-fluoro-α-D-arabinofuranosyl)-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 259738-08-4 HCAPLUS
CN 2H-Pyrazolo[3,4-d]pyrimidine, 2-(3,5-di-O-benzoyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 259738-09-5 HCAPLUS
CN 2H-Pyrazolo[3,4-d]pyrimidine, 2-(3,5-di-O-benzoyl-2-deoxy-2-fluoro-α-D-arabinofuranosyl)-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L65 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:49285 HCAPLUS

DN 122:240293
ED Entered STN: 08 Nov 1994
TI 8-Aza-1-deazapurine nucleosides as antiviral agents
AU Franchetti, P.; Messini, L.; Cappellacci, L.; Abu Sheikha, G.; Grifantini, M.; Guarracino, P.; De Montis, A.; Loi, A. G.; Marongiu, M. E.; **La Colla, P.**
CS Dip. Sci. Chim., Univ. Camerino, Camerino, 62032, Italy
SO Nucleosides & Nucleotides (1994), 13(8), 1739-55
CODEN: NUNUD5; ISSN: 0732-8311
DT Journal
LA English
CC 33-9 (Carbohydrates)
Section cross-reference(s): 1
GI



I II

AB Azadeazapurine nucleosides, e.g. I and II, were prepared via glycosidation of nucleobases. These dideoxy nucleosides and a series of previously synthesized 8-aza-1-deazapurine nucleosides were tested for activity against several DNA and RNA viruses, HIV-1 included. The α- and β-anomers of 2',3'-dideoxy-8-aza-1-deazaadenosine were found active as inhibitors of adenosine deaminase.
ST azadeazapurine nucleoside prepn virucide; dideoxyazadeazaadenosine inhibitor adenosine deaminase
IT Virucides and Virustats
(preparation and antiviral activity of azadeazapurine nucleosides)
IT Nucleosides, preparation
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antiviral activity of azadeazapurine nucleosides)
IT **14432-09-8 34625-29-1 34641-28-6 34664-98-7 142591-84-2 142591-89-7 142591-90-0 142591-95-5 142592-00-5 162181-03-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(preparation and antiviral activity of azadeazapurine nucleosides)
IT **162181-09-1P 162181-11-5P 162299-76-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antiviral activity of azadeazapurine nucleosides)
IT 9026-93-1, Adenosine deaminase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(preparation and antiviral activity of azadeazapurine nucleosides)

IT 34550-49-7 127306-45-0 162195-90-6 162299-72-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and antiviral activity of azadeazapurine nucleosides)
IT **162181-04-6P 162181-05-7P 162181-06-8P**
162181-07-9P 162181-10-4P 162299-73-2P
162299-74-3P 162299-77-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and antiviral activity of azadeazapurine nucleosides)
IT **162181-08-0P 162299-75-4P 162299-78-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antiviral activity of azadeazapurine nucleosides)
IT **14432-09-8 34625-29-1 34641-28-6**
34664-98-7 142591-84-2 142591-89-7
142591-90-0 142591-95-5 142592-00-5
162181-03-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(preparation and antiviral activity of azadeazapurine nucleosides)
RN 14432-09-8 HCAPLUS
CN 3H-Imidazo[4,5-b]pyridin-7-amine, 3-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 34625-29-1 HCAPLUS
CN 2H-1,2,3-Triazolo[4,5-b]pyridine, 7-chloro-2-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 34641-28-6 HCAPLUS
CN 3H-1,2,3-Triazolo[4,5-b]pyridine, 7-chloro-3-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 34664-98-7 HCAPLUS
CN 3H-1,2,3-Triazolo[4,5-b]pyridin-7-amine, 3-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142591-84-2 HCAPLUS
CN 3H-1,2,3-Triazolo[4,5-b]pyridin-7-amine, 3-(2-deoxy-β-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142591-89-7 HCAPLUS
CN 3H-1,2,3-Triazolo[4,5-b]pyridine, 7-chloro-3-(2-deoxy-β-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142591-90-0 HCAPLUS
CN 3H-1,2,3-Triazolo[4,5-b]pyridine, 7-chloro-3-(2-deoxy-α-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142591-95-5 HCAPLUS
CN 2H-1,2,3-Triazolo[4,5-b]pyridin-7-amine, 2-(2-deoxy-β-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142592-00-5 HCAPLUS
CN 2H-1,2,3-Triazolo[4,5-b]pyridin-7-amine, 2-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162181-03-5 HCAPLUS
CN 1H-1,2,3-Triazolo[4,5-b]pyridine, 7-chloro-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **162181-09-1P 162181-11-5P 162299-76-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antiviral activity of azadeazapurine nucleosides)
RN 162181-09-1 HCAPLUS
CN 2-Furanmethanol, 5-(7-amino-3H-1,2,3-triazolo[4,5-b]pyridin-3-yl)tetrahydro-, (2S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162181-11-5 HCAPLUS
CN 2-Furanmethanol, 5-(7-amino-4H-1,2,3-triazolo[4,5-b]pyridin-4-yl)tetrahydro-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162299-76-5 HCAPLUS
CN 2-Furanmethanol, 5-(7-amino-3H-1,2,3-triazolo[4,5-b]pyridin-3-yl)tetrahydro-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **162181-04-6P 162181-05-7P 162181-06-8P**
162181-07-9P 162181-10-4P 162299-73-2P
162299-74-3P 162299-77-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and antiviral activity of azadeazapurine nucleosides)

RN 162181-04-6 HCAPLUS
CN 3H-1,2,3-Triazolo[4,5-b]pyridine, 7-chloro-3-[5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]tetrahydro-2-furanyl]-, (2S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162181-05-7 HCAPLUS
CN 2H-1,2,3-Triazolo[4,5-b]pyridine, 7-chloro-2-[5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]tetrahydro-2-furanyl]-, (2R-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162181-06-8 HCAPLUS
CN 1H-1,2,3-Triazolo[4,5-b]pyridine, 7-chloro-1-[5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]tetrahydro-2-furanyl]-, (2S-trans)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162181-07-9 HCAPLUS
CN 2-Furanmethanol, 5-(7-chloro-3H-1,2,3-triazolo[4,5-b]pyridin-3-yl)tetrahydro-, (2S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162181-10-4 HCAPLUS
CN 4H-1,2,3-Triazolo[4,5-b]pyridin-7-amine, 4-[5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]tetrahydro-2-furanyl]-, (2R-cis)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162299-73-2 HCAPLUS
CN 3H-1,2,3-Triazolo[4,5-b]pyridine, 7-chloro-3-[5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]tetrahydro-2-furanyl]-, (2R-cis)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162299-74-3 HCAPLUS
CN 2-Furanmethanol, 5-(7-chloro-3H-1,2,3-triazolo[4,5-b]pyridin-3-yl)tetrahydro-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162299-77-6 HCAPLUS
CN 4H-1,2,3-Triazolo[4,5-b]pyridin-7-amine, 4-[5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]tetrahydro-2-furanyl]-, (2S-trans)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **162181-08-0P 162299-75-4P 162299-78-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antiviral activity of azadeazapurine nucleosides)
RN 162181-08-0 HCAPLUS
CN 2-Furanmethanol, 5-(7-chloro-2H-1,2,3-triazolo[4,5-b]pyridin-2-yl)tetrahydro-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162299-75-4 HCAPLUS
CN 2-Furanmethanol, 5-(7-chloro-2H-1,2,3-triazolo[4,5-b]pyridin-2-yl)tetrahydro-, (2S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162299-78-7 HCAPLUS
CN 2-Furanmethanol, 5-(7-amino-4H-1,2,3-triazolo[4,5-b]pyridin-4-yl)tetrahydro-, (2S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L65 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1994:473046 HCAPLUS
DN 121:73046
ED Entered STN: 20 Aug 1994
TI 8-Aza derivatives of 3-deazapurine nucleosides. Synthesis and in vitro evaluation of antiviral and antitumor activity
AU Franchetti, P.; Messini, L.; Cappellacci, L.; Grifantini, M.; Nocentini, G.; Guarracino, P.; Marongiu, M. E.; **La Colla, P.**
CS Dip. Sci. Chim., Univ. Camerino, Camerino, 62032, Italy
SO Antiviral Chemistry & Chemotherapy (**1993**), 4(6), 341-52
CODEN: ACCHEH; ISSN: 0956-3202
DT Journal
LA English
CC 1-3 (Pharmacology)
Section cross-reference(s): 33
AB The syntheses of 4-amino-1-(β-D-ribofuranosyl)-1H-1,2,3-triazolo[4,5-c]pyridine (8-aza-3-deazaadenosine), 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-1H-1,2,3-triazolo[4,5-c]pyridine (2'-deoxy-8-aza-3-deazaadenosine), and their N8 and N7 glycosylated analogs and 4-amino-1-(2,3-dideoxy-β-D-erythro-pentofuranosyl)-1H-1,2,3-triazolo [4,5-c]pyridine (2',3'-dideoxy-8-aza-3-deazaadenosine) were carried out by glycosylation of the 4-chloro-3H-1,2,3-triazolo[4,5-c]pyridine anion. The anomeric configuration as well as the position of glycosylation were determined by 1H-, 13C-NMR, UV and N.O.E. difference spectroscopy. 2'-Deoxy-8-aza-3-deazaadenosine and its parent compound 2'-deoxy-3-deazaadenosine were found active against ASFV and VSV. The 4-chloro-2-(β-D-ribofuranosyl)-2H-1,2,3-triazolo[4,5-c] pyridine was active against Coxsackie B1, whereas none of the 8-aza-3-deaza purine nucleosides, compound included, was active against HIV-1. The 6-chloro derivs. of 8-aza-3-deazapurine ribo- and 2'-deoxyribonucleosides and showed some activity against LoVo human colon adenocarcinoma.
ST deazapurine nucleoside prepn antiviral antitumor structure; antiviral deazapurine nucleoside prepn structure activity; antitumor deazapurine nucleoside prepn structure activity
IT Neoplasm inhibitors
Virucides and Virustats
(deazapurine nucleosides, preparation and structure-activity relations of)
IT Molecular structure-biological activity relationship
(neoplasm-inhibiting, of deazapurine nucleosides)
IT Molecular structure-biological activity relationship
(virucidal, of deazapurine nucleosides)
IT 36258-82-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(glycosylation of)
IT 4330-21-6 16205-59-7 134965-83-6 135092-93-2
RL: BIOL (Biological study)

(glycosylation of chlorotriazolopyridine with)
IT 154707-55-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(glycosylation of, with deoxydi(toluoyl)pentofuranosyl chloride)
IT **57680-38-3P 57680-40-7P 57680-44-1P**
154707-46-7P 154707-47-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antitumor and antiviral activity and reaction with liquid ammonia)
IT 110483-88-0P **154707-38-7P**, 2'-Deoxy-8-aza-3-deazaadenosine
154707-39-8P 154707-40-1P 154707-41-2P
154707-48-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antitumor and antiviral activity of)
IT **57680-35-0P 57680-36-1P 57680-37-2P**
154707-42-3P 154707-43-4P 154707-44-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deprotection of)
IT **154707-49-0P 154707-50-3P 154707-51-4P**
154707-52-5P 154707-53-6P 154707-54-7P
154801-75-9P 154801-76-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
IT **154707-45-6**
RL: BIOL (Biological study)
(preparation reaction with liquid ammonia)
IT **57680-38-3P 57680-40-7P 57680-44-1P**
154707-46-7P 154707-47-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antitumor and antiviral activity and reaction with liquid ammonia)
RN 57680-38-3 HCAPLUS
CN 2H-1,2,3-Triazolo[4,5-c]pyridine, 4-chloro-2-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 57680-40-7 HCAPLUS
CN 3H-1,2,3-Triazolo[4,5-c]pyridine, 4-chloro-3-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 57680-44-1 HCAPLUS
CN 1H-1,2,3-Triazolo[4,5-c]pyridine, 4-chloro-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154707-46-7 HCAPLUS
CN 3H-1,2,3-Triazolo[4,5-c]pyridine, 4-chloro-3-(2-deoxy-β-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154707-47-8 HCAPLUS
CN 1H-1,2,3-Triazolo[4,5-c]pyridine, 4-chloro-1-(2-deoxy-β-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 154707-38-7P, 2'-Deoxy-8-aza-3-deazaadenosine 154707-39-8P
154707-40-1P 154707-41-2P 154707-48-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antitumor and antiviral activity of)
RN 154707-38-7 HCAPLUS
CN 1H-1,2,3-Triazolo[4,5-c]pyridin-4-amine, 1-(2-deoxy-β-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154707-39-8 HCAPLUS
CN 2-Furanmethanol, 5-(4-amino-1H-1,2,3-triazolo[4,5-c]pyridin-1-yl)tetrahydro-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154707-40-1 HCAPLUS
CN 2H-1,2,3-Triazolo[4,5-c]pyridin-4-amine, 2-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154707-41-2 HCAPLUS
CN 3H-1,2,3-Triazolo[4,5-c]pyridin-4-amine, 3-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154707-48-9 HCAPLUS
CN 2H-1,2,3-Triazolo[4,5-c]pyridin-4-amine, 2-(2-deoxy-β-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **57680-35-0P 57680-36-1P 57680-37-2P**
154707-42-3P 154707-43-4P 154707-44-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deprotection of)
RN 57680-35-0 HCAPLUS
CN 1H-1,2,3-Triazolo[4,5-c]pyridine, 4-chloro-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 57680-36-1 HCAPLUS
CN 2H-1,2,3-Triazolo[4,5-c]pyridine, 4-chloro-2-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 57680-37-2 HCAPLUS
CN 3H-1,2,3-Triazolo[4,5-c]pyridine, 4-chloro-3-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154707-42-3 HCAPLUS
CN 2H-1,2,3-Triazolo[4,5-c]pyridine, 4-chloro-2-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-β-D-erythro-pentofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154707-43-4 HCAPLUS
CN 3H-1,2,3-Triazolo[4,5-c]pyridine, 4-chloro-3-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-β-D-erythro-pentofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154707-44-5 HCAPLUS
CN 1H-1,2,3-Triazolo[4,5-c]pyridine, 4-chloro-1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-β-D-erythro-pentofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **154707-49-0P 154707-50-3P 154707-51-4P**
154707-52-5P 154707-53-6P 154707-54-7P
154801-75-9P 154801-76-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 154707-49-0 HCAPLUS
CN 3H-1,2,3-Triazolo[4,5-c]pyridin-4-amine, 3-(2-deoxy-β-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154707-50-3 HCAPLUS
CN 1H-1,2,3-Triazolo[4,5-c]pyridine, 4-chloro-1-[5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]tetrahydro-2-furanyl]-, (2S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154707-51-4 HCAPLUS
CN 2-Furanmethanol, 5-(4-chloro-1H-1,2,3-triazolo[4,5-c]pyridin-1-yl)tetrahydro-, (2S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154707-52-5 HCAPLUS
CN 2H-1,2,3-Triazolo[4,5-c]pyridine, 4-methoxy-2-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154707-53-6 HCAPLUS
CN 1H-1,2,3-Triazolo[4,5-c]pyridine, 4-methoxy-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154707-54-7 HCAPLUS
CN 1H-1,2,3-Triazolo[4,5-c]pyridine, 1-(2-deoxy-β-D-erythro-pentofuranosyl)-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154801-78-9 HCAPLUS
CN 1H-1,2,3-Triazolo[4,5-c]pyridine, 4-chloro-1-[5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]tetrahydro-2-furanyl]-, (2R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154801-76-0 HCAPLUS
CN 2-Furanmethanol, 5-(4-chloro-1H-1,2,3-triazolo[4,5-c]pyridin-1-yl)tetrahydro-, (2R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **154707-45-6**
RL: BIOL (Biological study)
(preparation reaction with liquid ammonia)
RN 154707-45-6 HCAPLUS
CN 2H-1,2,3-Triazolo[4,5-c]pyridine, 4-chloro-2-(2-deoxy-β-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L65 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1994:457887 HCAPLUS
DN 121:57887
ED Entered STN: 06 Aug 1994
TI 2'-deoxy-2',2'-difluoro-(2,6,8-substituted) purine nucleosides having anti-viral and anti-cancer activity and intermediates
IN Grindley, Gerald Burr; Grossman, Cora Sue; Hertel, Larry Wayne; Kroin, Julian Stanley
PA Eli Lilly and Co., USA
SO Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DT Patent
LA English
IC ICM C07H019-04

ICS A61K031-70
CC 33-9 (Carbohydrates)
Section cross-reference(s): 1, 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 576227	A2	19931229	EP 1993-304815	19930621 <--
	EP 576227	A3	19940209		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	AU 9341347	A1	19931223	AU 1993-41347	19930618 <--
	CA 2098876	AA	19931223	CA 1993-2098876	19930621 <--
	NO 9302287	A	19931223	NO 1993-2287	19930621 <--
	BR 9302433	A	19940111	BR 1993-2433	19930621 <--
	HU 64553	A2	19940128	HU 1993-1821	19930621 <--
	JP 06056877	A2	19940301	JP 1993-149191	19930621 <--
	CN 1084178	A	19940323	CN 1993-107740	19930621 <--
PRAI	US 1992-902304		19920622 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
EP 576227	ICM	C07H019-04
	ICS	A61K031-70

OS MARPAT 121:57887
GI



I

AB Title compds. I [B = purine, azapurine, deazapurine base] were prepared Thus, 2-amino-6-chloropurine was glycosidated, treated with MeNH2, and deblocked to give I [B = 2-amino-6-methylaminopurine] which had an IC50 against human leukemia cells of 0.054 μg/mL and caused 56.9% inhibition of **hepatitis** B in vitro at 0.1 μg/mL.
ST deoxydifluororibofuranosylpurine nucleoside prepn antitumor virucide; purine deoxydifluororibofuranosyl
IT Neoplasm inhibitors
Virucides and Virustats
(deoxydifluororibofuranosylpurine nucleosides)
IT Nucleosides, preparation
RL: SPN (Synthetic preparation); PREP (Preparation)
(deoxydifluororibofuranosylpurine, preparation and antitumor and virucidal activity of)
IT 156058-20-7P 156058-22-9P 156058-23-0P 156058-26-3P 156058-27-4P
156058-28-5P 156058-30-9P 156058-31-0P 156058-32-1P 156058-34-3P
156058-37-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antitumor activity of)
IT 156058-29-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antitumor and virucidal activity of)
IT 155568-11-9P 155568-14-2P 156058-21-8P 156058-24-1P 156058-25-2P
156130-57-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(preparation and reaction of, in preparation of deoxydifluororibofuranosylpurine nucleosides)

IT 155568-11-9P 156058-33-2P 156058-35-4P 156058-36-5P
156058-38-7P 156058-39-8P 156058-40-1P 156058-41-2P
156058-42-3P 156058-43-4P 156058-44-5P 156058-45-6P 156058-46-7P
156058-47-8P 156058-48-9P 156100-12-8P 156124-74-2P 156124-75-3P
156124-76-4P **156124-77-5P** 156124-78-6P **156124-79-7P**
156124-80-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

IT 5451-40-1, 2,6-Dichloropurine 10310-21-1, 2-Amino-6-chloropurine
153012-08-9 155131-42-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of deoxydifluororibofuranosylpurine nucleosides)

IT **156058-38-7P 156058-39-8P 156124-77-5P**
156124-79-7P 156124-80-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 156058-38-7 HCAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 4,6-dichloro-1-(2-deoxy-2,2-difluoro-β-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 156058-39-8 HCAPLUS
CN 1H-Imidazo[4,5-c]pyridin-4-amine, 1-(2-deoxy-2,2-difluoro-β-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 156124-77-5 HCAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 5,7-dichloro-3-(3,5-di-O-benzoyl-2-deoxy-2,2-difluoro-β-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 156124-79-7 HCAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 4-chloro-1-(3,5-di-O-benzoyl-2-deoxy-2,2-difluoro-β-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 156124-80-0 HCAPLUS
CN 1H-Imidazo[4,5-c]pyridin-4-amine, 1-(3,5-di-O-benzoyl-2-deoxy-2,2-difluoro-β-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L65 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1994:183004 HCAPLUS
DN 120:183004

ED Entered STN: 16 Apr 1994
TI Therapeutic antiviral deoxythioribonucleosides
IN Koszalka, George Walter; Van Draanen, Nanine Agneta; Freeman, George Andrew; Short, Steven Andersen; Slater, Martin John
PA Wellcome Foundation Ltd., UK
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-70
CC 1-5 (Pharmacology)
Section cross-reference(s): 33, 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9401117	A1	19940120	WO 1993-GB1387	19930701 <--
	W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9345084	A1	19940131	AU 1993-45084	19930701 <--
PRAI	GB 1992-14170		19920702 <--		
	GB 1992-23181		19921105 <--		
	WO 1993-GB1387		19930701 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9401117	ICM	A61K031-70

OS MARPAT 120:183004
AB 2'-Deoxy-4'-thioribonucleosides and their physiol. acceptable salts, ~~esters, or~~ salts of such esters are useful for the manufacture of a medicament for the treatment or prophylaxis of retroviral, cytomegaloviral, varicella zoster viral, Epstein-Barr viral, human herpes virus 6, and **hepatitis** viral infections, including **hepatitis** B, coxsackie virus and **hepatitis C** virus infections. 2'-Deoxy-4'-thioguanosine (preparation given) inhibited **hepatitis** B virus with an IC50 of <0.0032 μM (74.5% inhibition) and a CCID50 of 13 μM. Formulation examples are also given.
ST antiviral deoxythioribonucleoside; thiodeoxyribonucleoside virus inhibitor; deoxythioguanosine **hepatitis** B virus inhibitor
IT Virucides and Virustats
(deoxythioribonucleosides)
IT Pharmaceutical dosage forms
(of deoxythioribonucleosides, for treatment of virus infection)
IT Escherichia coli
(trans-N-deoxyribosylase preparation from, for enzymic preparation of antiviral deoxythioribonucleosides)
IT Virus, animal
(Coxsackie, infection with, treatment of, with deoxythioribonucleosides)
IT Virus, animal
(Epstein-Barr, infection with, treatment of, with deoxythioribonucleosides)
IT Virus, animal
(cytomegalo-, infection with, treatment of, with deoxythioribonucleosides)
IT **Virus, animal**
(**hepatitis**, infection with, treatment of, with deoxythioribonucleosides)
IT **Virus, animal**
(**hepatitis B**, infection with, treatment of, with deoxythioribonucleosides)

IT **Virus, animal**
(**hepatitis C**, infection with, treatment of, with deoxythioribonucleosides)
IT Virus, animal
(human cytomegalo-, inhibition of, with deoxythioadenosine)
IT Virus, animal
(human herpes 6, infection with, treatment of, with deoxythioribonucleosides)
IT Pharmaceutical dosage forms
(oral, of deoxythioribonucleosides, for treatment of virus infection)
IT Pharmaceutical dosage forms
(parenterals, of deoxythioribonucleosides, for treatment of virus infection)
IT Virus, animal
(retro-, infection with, treatment of, with deoxythioribonucleosides)
IT Virus, animal
(varicella-zoster, infection with, treatment of, with deoxythioribonucleosides)
IT 9026-93-1, Adenosine deaminase
RL: BIOL (Biological study)
(in preparation of antiviral deoxythioguanosine)
IT 135656-41-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of antiviral deoxythioadenosine)
IT 153585-36-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
IT 135656-33-6P 153666-10-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of and virus infection inhibition with)
IT 9026-86-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, from Escherichia coli, for enzymic preparation of antiviral deoxythioribonucleosides)
IT 153585-34-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, from aminomethoxypurine, trans-N-deoxyribosylase in)
IT 87-42-3, 6-Chloropurine 153585-35-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of antiviral deoxythioadenosine)
IT 134111-32-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with aminomethoxypurine, trans-N-deoxyribosylase in)
IT 20535-83-5, 2-Amino-6-methoxypurine
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with deoxythiouridine, trans-N-deoxyribosylase in)
IT 153585-20-7 153585-20-7D, halo derivs. 153585-21-8 153585-22-9 153585-22-9D, halo derivs. 153585-23-0 153585-24-1 153585-25-2 153585-26-3 153585-26-3D, halo derivs. 153585-27-4 153585-28-5 153585-28-5D, halo derivs. 153585-29-6 **153585-30-9** **153585-30-9D**, halo derivs. **153585-31-0** **153585-32-1** **153585-32-1D**, halo derivs. **153585-33-2** 153666-07-0 153666-08-1 153666-08-1D, halo derivs. 153666-09-2 153666-10-5D, halo derivs.
RL: BIOL (Biological study)
(virus infection inhibition with)
IT **153585-30-9** **153585-30-9D**, halo derivs. **153585-31-0** **153585-32-1** **153585-32-1D**, halo derivs. **153585-33-2**
RL: BIOL (Biological study)
(virus infection inhibition with)

RN 153585-30-9 HCAPLUS
CN 1H-Imidazo[4,5-c]pyridin-4-amine, 1-(2-deoxy-4-thio-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 153585-30-9 HCAPLUS
CN 1H-Imidazo[4,5-c]pyridin-4-amine, 1-(2-deoxy-4-thio-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 153585-31-0 HCAPLUS
CN 1H-Imidazo[4,5-c]pyridine-4,6-diamine, 1-(2-deoxy-4-thio-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 153585-32-1 HCAPLUS
CN 4H-Imidazo[4,5-c]pyridin-4-one, 1-(2-deoxy-4-thio-D-erythro-pentofuranosyl)-1,5-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 153585-32-1 HCAPLUS
CN 4H-Imidazo[4,5-c]pyridin-4-one, 1-(2-deoxy-4-thio-D-erythro-pentofuranosyl)-1,5-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 153585-33-2 HCAPLUS
CN 4H-Imidazo[4,5-c]pyridin-4-one, 6-amino-1-(2-deoxy-4-thio-D-erythro-pentofuranosyl)-1,5-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L65 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1992:584333 HCAPLUS
DN 117:184333
ED Entered STN: 15 Nov 1992
TI Nucleobase transporter-mediated permeation of 2',3'-dideoxyguanosine in human erythrocytes and human T-lymphoblastoid CCRF-CEM cells
AU Gati, Wendy P.; Paterson, Alan R. P.; Tyrrell, David L. J.; Cass, Carol E.; Moravek, Josef; Robins, Morris J.
CS Dep. Pharmacol., Univ. Alberta, Edmonton, AB, T6G 2H7, Can.
SO Journal of Biological Chemistry (1992), 267(31), 22272-6
CODEN: JBCHA3; ISSN: 0021-9258

DT Journal
LA English
CC 1-5 (Pharmacology)
AB Several 2',3'-dideoxynucleosides (ddNs), agents that inhibit the replication of human immunodeficiency virus and **hepatitis** B virus, enter mammalian cells by simple diffusion. In this report, the authors show that the membrane permeation of 2',3'-dideoxyguanosine (ddG) in human erythrocytes and CCRF-CEM cells, in contrast with that of other ddNs, is transporter-mediated. Inward fluxes of ddG in both cell types were inhibited by adenine, hypoxanthine, and acyclovir, but not by inhibitors of nucleoside transport (nitrobenzylthioinosine, dipyridamole, dilazep). Fluxes of ddG in human erythrocytes were attributable to a single, rate-saturable process (Km, 380 ± 90 μM and Vmax, 7.9 ± 0.8 pmol/s/μL cell water) that was competitively inhibited by adenine (Ki, 16 μM). These results showed that ddG entered human erythrocytes and CCRF-CEM cells by a transporter-mediated process that was also the basis for entry of purine nucleobases. In contrast, inward fluxes of 2,6-diaminopurine-2',3'-dideoxyriboside (ddDAPR), a prodrug of ddG, were not affected by purine nucleobases or nucleoside transport inhibitors in either cell type. Thus, the permeation properties of ddDAPR resembled those of 2',3'-dideoxyadenosine, a diffusional permeant (cell uptake is transporter-independent), and contrasted with those of ddG, the deamination product of ddDAPR. This study demonstrated that the nucleobase moiety of ddNs is an important determinant of membrane permeation.
ST dideoxyguanosine membrane permeation nucleobase transporter; erythrocyte nucleobase transport system dideoxyguanosine permeation; lymphoblast nucleobase transport system dideoxyguanosine permeation
IT Erythrocyte
(dideoxyguanosine permeation in human, nucleobase transporter mediation of)
IT Virucides and Virustats
(dideoxyguanosine, nucleobase transporter-mediated membrane permeation of, in human cells)
IT Partition
(of dideoxynucleosides between octanol and buffer)
IT Animal cell line
(CCRF-CEM, dideoxyguanosine permeation in human, nucleobase transporter mediation of)
IT Biological transport
(permeation, of dideoxyguanosine in human erythrocytes and T-lymphoblastoid CCRF-CEM cells, nucleobase transporter mediation of)
IT 58-32-2, Dipyridamole 58-63-9, Inosine 68-94-0, Hypoxanthine 73-24-5, Adenine, biological studies 961-07-9, 2'-Deoxyguanosine **13877-76-4**, Formycin B 35898-87-4, Dilazep 38048-32-7 59277-89-3, Acyclovir
RL: BIOL (Biological study)
(dideoxyguanosine transport by human erythrocytes and T-lymphoblastoid CCRF-CEM cells response to)
IT 85326-06-3, 2',3'-Dideoxyguanosine
RL: PROC (Process)
(nucleobase transporter-mediated permeation of, in human erythrocytes and T-lymphoblastoid CCRF-CEM cells)
IT 4097-22-7, 2',3'-Dideoxyadenosine 69655-05-6, 2',3'-Dideoxyinosine 107550-73-2
RL: BIOL (Biological study)
(transport of, by human erythrocytes and T-lymphoblastoid CCRF-CEM cells, nucleobase transport system in relation to)
IT **13877-76-4**, Formycin B
RL: BIOL (Biological study)
(dideoxyguanosine transport by human erythrocytes and T-lymphoblastoid CCRF-CEM cells response to)
RN 13877-76-4 HCAPLUS

CN 7H-Pyrazolo[4,3-d]pyrimidin-7-one, 1,4-dihydro-3-β-D-ribofuranosyl- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



L65 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1992:59866 HCAPLUS
DN 116:59866
ED Entered STN: 21 Feb 1992
TI Synthesis and evaluation of anti-HIV-1 and antitumor activity of 2',3'-didehydro-2',3'-dideoxy-3-deazaadenosine, 2',3'-dideoxy-3-deazaadenosine and some 2',3'-dideoxy-3-deazaadenosine 5'-dialkyl phosphates
AU Franchetti, P.; Cappellacci, L.; Cristalli, G.; Grifantini, M.; Pani, A.; La Colla, P.; Nocentini, G.
CS Dip. Sci. Chim., Univ. Camerino, Camerino, 62032, Italy
SO Nucleosides & Nucleotides (1991), 10(7), 1551-62
CODEN: NUNUD5; ISSN: 0732-8311
DT Journal
LA English
CC 33-9 (Carbohydrates)
Section cross-reference(s): 1
GI



III

AB The 4-amino-1-(2,3-dideoxy-β-D-glycero-pent-2-enofuranosyl)-1H-imidazo[4,5-c]pyridine (I), 4-amino-1-(2,3-dideoxy-β-D-glycero-pentofuranosyl)-1H-imidazo[4,5-c]pyridine (II), and 3-deaza analogs of the anti-HIV agents 2',3'-didehydro-2',3'-dideoxyadenosine and 2',3'-dideoxyadenosine, have been synthesized. The reaction of 3-deazaadenosine with 2-acetoxyisobutyryl bromide yielded a mixture of cis and trans 2',3'-halo acetates which was converted into olefinic nucleoside I on treatment with a Zn/Cu couple and then with NH3/MeOH. A number of

phosphate triester derivs. of II have also been prepared Nucleotides III (R = Et, Pr, Bu) and 3-deazaadenosine have shown anti-HIV activity at non-cytotoxic doses. III have also shown significant cytostatic activity against murine colon adenocarcinoma cells.

ST deoxydeazaadenosine phosphate virucide neoplasm inhibitor; dehydrodideoxyadenosine prepn virucide neoplasm inhibitor; deazaadenosine didehydrodideoxy virucide neoplasm inhibitor; nucleotide dideoxydeaza virucide neoplasm inhibitor

IT Neoplasm inhibitors
Virucides and Virustats
(dideoxydeazaadenosine phosphates as)

IT Nucleotides, polymers
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(di-, deoxy-, deazaadenine, preparation and antiviral and antitumor activity of)

IT Nucleotides, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(dideoxy-, deazaadenine, preparation and antiviral and antitumor activity of)

IT 4097-22-7 7057-48-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(antiviral and antitumor activity of)

IT 814-49-3 819-43-2 2510-89-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(phosphorylation by, of dideoxydeazaadenosine)

IT **138352-56-4P 138352-57-5P 138352-58-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antiviral and antitumor activity of)

IT **138352-55-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, hydrogenation, antiviral and antitumor activity of)

IT **130948-34-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, phosphorylation, antiviral and antitumor activity of)

IT 40635-67-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with deazaadenosine)

IT **6736-58-9**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(sequential bromination and elimination reaction, antiviral, and antitumor activity of)

IT **138352-56-4P 138352-57-5P 138352-58-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antiviral and antitumor activity of)

RN 138352-56-4 HCAPLUS

CN Phosphoric acid, [5-(4-amino-1H-imidazo[4,5-c]pyridin-1-yl)tetrahydro-2-furanyl]methyl diethyl ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 138352-57-5 HCAPLUS
CN Phosphoric acid, [5-(4-amino-1H-imidazo[4,5-c]pyridin-1-yl)tetrahydro-2-furanyl]methyl dipropyl ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 138352-58-6 HCAPLUS
CN Phosphoric acid, [5-(4-amino-1H-imidazo[4,5-c]pyridin-1-yl)tetrahydro-2-furanyl]methyl dibutyl ester (9CI) (CA INDEX NAME)



IT **138352-55-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, hydrogenation, antiviral and antitumor activity of)
RN 138352-55-3 HCAPLUS
CN 2-Furanmethanol, 5-(4-amino-1H-imidazo[4,5-c]pyridin-1-yl)-2,5-dihydro-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 130948-34-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, phosphorylation, antiviral and antitumor activity of)
RN 130948-34-4 HCAPLUS
CN 2-Furanmethanol, 5-(4-amino-1H-imidazo[4,5-c]pyridin-1-yl)tetrahydro-, (2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 6736-58-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(sequential bromination and elimination reaction, antiviral, and antitumor activity of)
RN 6736-58-9 HCAPLUS
CN 1H-Imidazo[4,5-c]pyridin-4-amine, 1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L65 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1990:544908 HCAPLUS
DN 113:144908
ED Entered STN: 27 Oct 1990

TI Inhibition of **hepatitis** A virus replication in vitro by antiviral compounds

AU Crance, J. M.; Biziagos, E.; Passagot, J.; Van Cuyck-Gandre, H.; Deloince, R.

CS Unite Biol. Mol., Cent. Rech. Serv. Sante Armees, La Tronche, 38702, Fr.

SO Journal of Medical Virology (1990), 31(2), 155-60
CODEN: JMVIDB; ISSN: 0146-6615

DT Journal

LA English

CC 1-5 (Pharmacology)

AB Forty antiviral compds. were screened for inhibitory effect on **hepatitis** A virus (HAV) antigen expression in the human hepatoma cell line PLC/PRF/5. **Ribavirin**, amantadine, glycyrrhizin, and pyrazofurin were selected in this screening test and were studied further. The selectivity indexes of these four compds., calculated as the ratio of 50% cytotoxic dose (determined by the trypan blue exclusion and by inhibition of [3H]leucine incorporation) to the 50% ED (determined by the viral antigen expression), were 4.6 and 3.0 with **ribavirin**, 5.3 and 5.9 with amantadine, 15.2 and 16.9 with glycyrrhizin, and 45.4 and 74.6 with pyrazofurin. All four compds. resulted in concentration-dependent redns. of HAV antigen expression and HAV infectivity. **Ribavirin**, amantadine, pyrazofurin, and glycyrrhizin emerged, from the present study, as promising candidates for chemotherapy of acute **hepatitis** A.

ST antiviral **hepatitis** A virus; **ribavirin** antiviral **hepatitis** A virus; amantadine antiviral **hepatitis** A virus; glycyrrhizin antiviral **hepatitis** A virus; pyrazofurin antiviral **hepatitis** A virus

IT Virucides and Virustats
(against **hepatitis** A virus, screening for, in human hepatoma cells)

IT Saponins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiviral activity of, against **hepatitis** A virus, in human hepatoma cells)

IT **Virus, animal**
(**hepatitis A**, infection with, antiviral screening for therapy of, in human hepatoma cells)

IT Pentosans
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sulfates, antiviral activity of, against **hepatitis** A virus, in human hepatoma cells)

IT 50-02-2, Dexamethasone 50-23-7, Hydrocortisone 50-81-7, Ascorbic acid, biological studies 54-21-7, Sodium salicylate 54-25-1, 6-Azauridine 58-08-2, Caffeine, biological studies 58-32-2, Dipyridamole 66-81-9, Cycloheximide 73-03-0, Cordycepin 85-31-4, 6-Mercaptoguanosine 89-83-8 113-00-8, Guanidine 141-84-4, Rhodanine 154-23-4, Catechin 320-67-2, 5-Azacytidine 378-44-9, Betamethasone 480-18-2, Taxifolin 768-94-5, Amantadine 1024-99-3, 5-Iodouridine 1123-54-2, 8-Azaadenine 1147-23-5, 5-Iodocytidine 1397-89-3, Amphotericin B 1405-86-3, Glycyrrhizin 1445-07-4, Pseudouridine 6990-06-3, Fusidic acid 6998-60-3, Rifamycin 9005-49-6, Heparin, biological studies 9042-14-2, Dextran sulfate 9072-19-9, Fucoidan 11089-65-9, Tunicamycin 13292-46-1, Rifampicin **13877-76-4** 23205-42-7, 3-Deazauridine 26001-38-7, 8-Mercaptoguanosine 30868-30-5, Pyrazofurin **36791-04-5, Ribavirin**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antiviral activity of, against **hepatitis** A virus, in human hepatoma cells)

IT **13877-76-4 36791-04-5, Ribavirin**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiviral activity of, against **hepatitis** A virus, in human hepatoma cells)

RN 13877-76-4 HCAPLUS
CN 7H-Pyrazolo[4,3-d]pyrimidin-7-one, 1,4-dihydro-3-β-D-ribofuranosyl- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 36791-04-5 HCAPLUS
CN 1H-1,2,4-Triazole-3-carboxamide, 1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L65 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN
AN **1984:603955** HCAPLUS
DN **101:203955**
TI Broad-spectrum **synergistic** antiviral activity of selenazofurin and **ribavirin**
AU Kirsi, Jorma J.; McKernan, Patricia A.; Burns, Noah J., III; North, James A.; Murray, Byron K.; Robins, Roland K.
CS Dep. Microbiol., Brigham Young Univ., Provo, UT, 84602, USA
SO Antimicrobial Agents and Chemotherapy (**1984**), 26(4), 466-75
CODEN: AMACCQ; ISSN: 0066-4804
DT Journal
LA English
CC 1-5 (Pharmacology)
AB The antiviral effects of selenazofurin [**83705-13-9**], **ribavirin** [**36791-04-5**], and 3-deazaguanosine [**56039-11-3**] were investigated sep. and in various **combinations** in an in vitro study. The **combination** interactions were evaluated at seven drug concns., graphically (isobolograms) or by using fractional inhibitory concentration indexes against mumps, measles, parainfluenza virus type 3, vaccinia and herpes simplex virus type 2 viruses in Vero and HeLa cells.

Selenazofurin in **combination** with **ribavirin** produced the greatest **synergistic** antiviral activity. However, the degree of **synergy** depended on the virus and cell line used. In contrast, selenazofurin **combined** with 3-deazaguanosine consistently yielded an indifferent or an antagonistic response, or both, whereas the **ribavirin**-3-deazaguanosine interaction was additive against the same viruses. Single-drug cytotoxicity was minimal for the cytostatic agents selenazofurin and **ribavirin** but was markedly higher for cytocidal 3-deazaguanosine, as determined by relative plating efficiency after drug exposure. The drug **combinations** did not significantly increase cytotoxicity (they were only additive) when used on uninfected cells. Therefore, the enhanced antiviral activities of the drug **combinations** (shown to be **synergistic**) were due to specific effects against viral replication. These results indicated that in Vero and HeLa cells (i) the **combination** of selenazofurin and **ribavirin** produced and enhanced antiviral effect, thus requiring smaller amts. of drug to cause the same antiviral effect relative to a single compound; (ii) selenazofurin when compared with **ribavirin** and -deazaguanosine appeared to have a somewhat different mode of antiviral action; (iii) 3-deazaguanosine **combined** with selenazofurin was an unsuitable antiviral **combination**; and (i.v.) the antiviral activity of 3-deazaguanosine appeared to be due largely to its general overall cytotoxic effect.

ST antiviral **ribavirin** selenazofurin **combination**; deazaguanine antiviral **combination**

IT **36791-04-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(antiviral activity of deazaguanine or selenazofurin and, broad-spectrum **synergistic**)

IT 83705-13-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(antiviral activity of **ribavirin** or deazaguanine and, broad-spectrum **synergistic**)

IT **56039-11-3**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(antiviral activity of **ribavirin** or selenazofurin and, broad-spectrum **synergistic**)

IT **36791-04-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(antiviral activity of deazaguanine or selenazofurin and, broad-spectrum **synergistic**)

RN 36791-04-5 HCAPLUS

CN 1H-1,2,4-Triazole-3-carboxamide, 1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **56039-11-3**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(antiviral activity of **ribavirin** or selenazofurin and, broad-spectrum **synergistic**)

RN 56039-11-3 HCAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 6-amino-1,5-dihydro-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L65 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1969:46065 HCAPLUS

DN 70:46065

ED Entered STN: 12 May 1984

TI Chemotherapeutic studies on mouse **hepatitis** virus. III. Antiviral effect of some pharmacodynamic drugs

AU Kanoh, Seizaburo

CS Nat. Inst. Hyg. Sci., Osaka, Japan

SO Chemotherapy (Tokyo) (1968), 16(6), 789-91
CODEN: NKRZAZ; ISSN: 0009-3165

DT Journal

LA English

CC 15 (Pharmacodynamics)

AB Xenaldial (100 μg./ml.) completely inactivated mouse **hepatitis** virus EHF-120 in vitro, but this drug (125 mg./kg./day, s.c., on the 1st 3 days of infection) did not have an antiviral effect in mice. Treatment with s.c. injections of formicin (10-20 mg./kg./day) or p-carboxy-N-methylacetylnicotinic acid (?) (125-500 mg./kg./day) on the 1st 3 days of infection decreased the mortality of infected mice from a control level of 57 to 42.8 and 37.5%, resp., in 1 group of mice. Treatment of mice with s.c. injections of Benadryl-HCl (0.5 mg./kg./day, for 4 days, beginning 2 days before infection) decreased the mortality rate from a control level of 43 to 28.5%.

ST antiviral effect formicin; formicin antiviral effect; xenaldial **hepatitis** virus; **hepatitis** virus nicotinates; virus **hepatitis** nicotinates; nicotinates **hepatitis** virus; Benadryl **hepatitis** virus control

IT Virucides

IT Viruses, animal
(mouse **hepatitis**, infection with, pharmaceuticals effect on)

IT 59-67-6, Nicotinic acid 147-24-0 1094-85-5 **6742-12-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(virucidal activity of)

IT **6742-12-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(virucidal activity of)

RN 6742-12-7 HCAPLUS

CN D-Ribitol, 1-C-(7-amino-1H-pyrazolo[4,3-d]pyrimidin-3-yl)-1,4-anhydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=>